TAS-102 plus Bevacizumab combination as first-line treatment in elderly patients with metastatic colorectal cancer, phase 2 trial

ABSTRACT: Interventions: TAS-102: 35mg/m2 given orally twice a day in a 28-day cycle, 2-week cycle of 5 days treatment followed by a 2-day rest period, and then a 14-day rest period Bevacizumab: 5mg/kg given intravenously in a 2-week cycle Primary outcome(s): relative dose intensity Study Design: Single arm Non-randomized

DISEASE(S): Metastaic Colorectal Cancer

PROVIDER: 2635519 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR